Molecular diagnostics company SML Genetree (CEO Dongsoo Lee) announced on the 1st that it participated in the "2024 American Association for Clinical Chemistry (ADLM)" held in Chicago, Illinois, showcasing its new brand "NamuPlex" to global attendees.
ADLM is one of the world's largest diagnostics exhibition, and this year, the event was held from July 28 to August 1 at McCormick Place Convention Center, featuring over 900 global biotech companies.
SML Genetree established its U.S. subsidiary in 2020 to accelerate global expansion into the U.S. and South American markets and has been participating in the ADLM since 2021. At the 2024 ADLM, SML Genetree introduced its new brand, "NamuPlex," showcasing the latest product line to global customers and identifying new distribution partners.
Having a name of Namu which means Tree in Korea, "NamuPlex" symbolizes vitality, growth, and expansion in the diagnostics field, with key products including Respiratory Pathogen, STD, H. pylori-CLA, and MTBC/NTM, recognized for their quality in various countries, including Asia and the Middle East.
CEO Dongsoo Lee stated, "It is significant to introduce SML Genetree's NamuPlex products to the global market through this exhibition. We will continue to work on promoting our brand and establishing new partnerships with global customers, including those in South America. Additionally, this event marks the beginning of our expansion into the European and American markets for our highly praised Respiratory Pathogen and STD products."
SML Genetree develops a variety of diagnostic products, from infectious diseases to NGS panels for cancer and rare disease diagnostics. The company has recently launched a global business division to accelerate its expansion into the international market. SML Genetree is part of the Samkwang Biotree Group, along with affiliated companies Samkwang Medical Lab, Samkwang Labtree, SML Meditree, and SML Biopharm.
Source: NewsWire (https://www.newswire.co.kr/newsRead.php?no=994364)
Molecular diagnostics company SML Genetree (CEO Dongsoo Lee) announced on the 1st that it participated in the "2024 American Association for Clinical Chemistry (ADLM)" held in Chicago, Illinois, showcasing its new brand "NamuPlex" to global attendees.
ADLM is one of the world's largest diagnostics exhibition, and this year, the event was held from July 28 to August 1 at McCormick Place Convention Center, featuring over 900 global biotech companies.
SML Genetree established its U.S. subsidiary in 2020 to accelerate global expansion into the U.S. and South American markets and has been participating in the ADLM since 2021. At the 2024 ADLM, SML Genetree introduced its new brand, "NamuPlex," showcasing the latest product line to global customers and identifying new distribution partners.
Having a name of Namu which means Tree in Korea, "NamuPlex" symbolizes vitality, growth, and expansion in the diagnostics field, with key products including Respiratory Pathogen, STD, H. pylori-CLA, and MTBC/NTM, recognized for their quality in various countries, including Asia and the Middle East.
CEO Dongsoo Lee stated, "It is significant to introduce SML Genetree's NamuPlex products to the global market through this exhibition. We will continue to work on promoting our brand and establishing new partnerships with global customers, including those in South America. Additionally, this event marks the beginning of our expansion into the European and American markets for our highly praised Respiratory Pathogen and STD products."
SML Genetree develops a variety of diagnostic products, from infectious diseases to NGS panels for cancer and rare disease diagnostics. The company has recently launched a global business division to accelerate its expansion into the international market. SML Genetree is part of the Samkwang Biotree Group, along with affiliated companies Samkwang Medical Lab, Samkwang Labtree, SML Meditree, and SML Biopharm.
Source: NewsWire (https://www.newswire.co.kr/newsRead.php?no=994364)